Ionis Pharmaceuticals IONS Net realized gains (losses)
Net realized gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's net realized gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's net realized gains (losses)?
- Ionis Pharmaceuticals (IONS) reported net realized gains (losses) of $22.58M in Q1 2026.
- How has Ionis Pharmaceuticals's net realized gains (losses) changed year-over-year?
- Ionis Pharmaceuticals's net realized gains (losses) increased by 1321.4% year-over-year, from -$1.85M to $22.58M.
- What is the long-term trend for Ionis Pharmaceuticals's net realized gains (losses)?
- Over 3 years (2021 to 2025), Ionis Pharmaceuticals's net realized gains (losses) has grown at a 105.2% compound annual growth rate (CAGR), from $1.09M to $9.44M.
- What does net realized gains (losses) mean?
- The profit or loss realized from selling investment securities.
- How do you interpret net realized gains (losses)?
- Higher gains indicate successful treasury management or favorable market conditions for the company's investment portfolio.
- How does net realized gains (losses) compare across companies?
- Common for companies with large cash reserves or strategic investment portfolios; peers report this to isolate core operating performance.